Gland Pharma Limited announced the resignation of its Chief Executive Officer (CEO) and Key Managerial Personnel, Mr. Shyamakant Giri, effective from the close of business on April 30, 2026. The resignation was accepted by the Board of Directors following a recommendation from the Nomination and Remuneration Committee. Mr. Giri cited the need to pursue new opportunities in his resignation letter dated February 24, 2026. The company expressed sincere appreciation for his leadership during his tenure.
Key Management Personnel Change Announced
Gland Pharma Limited has formally notified exchanges regarding a significant change in its senior leadership team. Mr. Shyamakant Giri, who served as the Chief Executive Officer (CEO) and a Key Managerial Personnel, has resigned from his position.
Effective Date and Board Acceptance
Mr. Giri’s last day of employment with the Company will be April 30, 2026. This decision follows his resignation letter, dated February 24, 2026, submitted to the Executive Chairman. The Board of Directors, acting on the recommendation of the Nomination and Remuneration Committee, officially accepted the resignation on March 03, 2026.
Appreciation and Transition Commitment
The Board and the entire Gland Pharma family formally acknowledged and extended their sincere appreciation for Mr. Giri’s leadership and contributions. In his resignation letter, Mr. Giri stated that the decision was made after careful consideration to pursue new opportunities and thanked the management for the support received during his tenure. Furthermore, he assured the company of his commitment to ensuring a smooth transition and the effective handover of all responsibilities before his departure.
Details of Change
The required disclosure information confirms that the reason for the change is the resignation of Mr. Shyamakant Giri as CEO and KMP. No other specific details regarding relationships or previous circular references were deemed applicable for this announcement beyond the basic particulars of the departure.
Source: BSE
